Key Highlights

  • PMV Pharmaceuticals reported updated interim PYNNACLE Phase 2 ovarian cancer data for rezatapopt.
  • The data showed a 46% ORR among 76 evaluable TP53 Y220C patients and a 10-month median duration of response.
  • FDA feedback supports a planned Q1 2027 NDA submission for accelerated approval.
  • The company separately finalized pricing of a $50.8 million upsized public offering of shares and warrants at $1.21 each.

PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) reported updated interim PYNNACLE Phase 2 ovarian cancer data for rezatapopt showing a 46% ORR among 76 evaluable TP53 Y220C patients and a 10-month median duration of response.

What Happened

FDA feedback supports a planned Q1 2027 NDA submission for Accelerated Approval in platinum-resistant or refractory ovarian cancer. The company separately finalized the pricing of a $50.8 million upsized public offering of shares and warrants at $1.21 each, with proceeds earmarked to advance rezatapopt's clinical development and regulatory pathway.

Market Reaction

The disclosed information does not include stock price or trading data for PMV Pharmaceuticals following the data update and offering pricing.

Outlook

The planned NDA submission in early 2027 for rezatapopt in platinum-resistant or refractory ovarian cancer represents the next major disclosed milestone, now supported by the newly raised capital.